# Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients

> **NCT02215798** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 269 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Cymbalta

## Key facts

- **NCT ID:** NCT02215798
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2014-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215798, "Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02215798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*